Author Index for Volume 14

Amato DA, 523
Anderson GL, 308
Anderson MM, Jr, 123
Anthonisen NR, 68S
Appel LJ, 569
Armstrong JA, 523
Ashish S, 467

Backlund J-Y, 123
Bailey WC, 3S
Balmes J, 308
Barnhart S, 308
Bartlett JG, 6, 523
Beck RW, 123, 143
Berendes HW, 179
Berge KG, 350
Bjornson-Benson WM, 38S, 52S
Boissel J-P, 344
Braga M, 296
Brooks HB, 500
Brown BW, Jr, 109
Buchwald H, 500
Buist AS, 20S, 52S

Cherniack M, 308
Clark CM, Jr, 30
Cleary PA, 123, 143
Coe PR, 19
Cole BF, 485
Collaborative Ocular Melanoma Study Group, 362
Collins D, 6
Cone J, 308
Connett JE, 3S, 20S, 38S
Corle DK, 253
Counts GW, 523
Coyne T, 538
Cullen MR, 308

Dafni U, 523
Daniels K, 38S
Davis BR, 350
de Velasco A, 538
DeMets D, 6
DeMets DL, 183
Deykin D, 6
Drabik MJ, 538
Dumont J-M, 209
Durkin DA, 20S

Edelstein C, 325

Feorino P, 6
Finlay RA, 538
Fitch LL, 500
Fleming TR, 183

Gail M, 6
Gail MH, 253
Gassman JJ, 538
Gelber RD, 485
George SL, 511
Gilbert PR, 123
Gladstone P, 45
Glass A, 308
Godfrey E, 523
Goldhirsch A, 485
Goodman GE, 308
Grizzle JE, 308

Halpern J, 109
Hamilton JD, 6
Hammer S, 308
Hansen BJ, 500
Hartigan PM, 6
Hawkins CM, 350
Higginson L, 45
Hillis A, 560
Hughes JR, 176

International Breast Cancer Study Group, 485

Jobe AH, 75
Johnson CA, 143
Johnson JW, 500

Keltner JL, 143
Kenny DJ, 123
Keogh JP, 308
Kiefer S, 538
Kimball B, 45
Kjelsberg MO, 20S
Korn EL, 286
Kusek JW, 3S, 538

Lachin JM, 471
Lakatos E, 350
Lange N, 247
Langenberg P, 467
Lee YJ, 179
Leedom JM, 523
Leite MLC, 296
LeMay M, 45
Lespérance J, 45
Louis TA, 252
Lund B, 325
Lung Health Study Research Group, 1S, 3S, 20S, 38S
Lunghofer B, 523

Manfreda J, 68S
Manske KA, 52S
Mark SD, 79
Marubini E, 296
Matts JP, 500
McKellar J, 568
McMahon RP, 244
Meinert CL, 255
Meyskens F, Jr, 308
Miller LL, 286
Moyé LA, 249, 350

ODES Investigators, 229
O'Hara P, 3S
Omenn GS, 308, 325
Optic Neuritis Study Group, 123, 143
Owens GR, 20S

Peterson B, 511
Petroccione A, 296
Pettit P, 261
Piantadosi S, 562
Pirotta N, 296
PMA Biostatistics and Medical Ad Hoc Committee on Interim Analysis, 160
POSCH Group, 500
Powers SN, 538
Pressel S, 350
Pritchett W, 6
Probstfield JL, 350

Recruitment Directors of the Lung Health Study for the Lung Health Study Research Group, 20S

0197-2456/93/$6.00

Controlled Clinical Trials 13:572–573 (1993)
© Elsevier Science Publishing Co., Inc. 1993
655 Avenue of the Americas, New York, New York, 10010

Author Index for Volume 14

Amato DA, 523
Anderson GL, 308
Anderson MM, Jr, 123
Anthonisen NR, 68S
Appel LJ, 569
Armstrong JA, 523
Ashish S, 467

Backlund J-Y, 123
Bailey WC, 3S
Balmes J, 308
Barnhart S, 308
Bartlett JG, 6, 523
Beck RW, 123, 143
Berendes HW, 179
Berge KG, 350
Bjornson-Benson WM, 38S, 52S
Boissel J-P, 344
Braga M, 296
Brooks HB, 500
Brown BW, Jr, 109
Buchwald H, 500
Buist AS, 20S, 52S

Cherniack M, 308
Clark CM, Jr, 30
Cleary PA, 123, 143
Coe PR, 19
Cole BF, 485
Collaborative Ocular Melanoma Study Group, 362
Collins D, 6
Cone J, 308
Connett JE, 3S, 20S, 38S
Corle DK, 253
Counts GW, 523
Coyne T, 538
Cullen MR, 308

Dafni U, 523
Daniels K, 38S
Davis BR, 350
de Velasco A, 538
DeMets D, 6
DeMets DL, 183
Deykin D, 6
Drabik MJ, 538
Dumont J-M, 209
Durkin DA, 20S

Edelstein C, 325

Feorino P, 6
Finlay RA, 538
Fitch LL, 500
Fleming TR, 183

Gail M, 6
Gail MH, 253
Gassman JJ, 538
Gelber RD, 485
George SL, 511
Gilbert PR, 123
Gladstone P, 45
Glass A, 308
Godfrey E, 523
Goldhirsch A, 485
Goodman GE, 308
Grizzle JE, 308

Halpern J, 109
Hamilton JD, 6
Hammer S, 308
Hansen BJ, 500
Hartigan PM, 6
Hawkins CM, 350
Higginson L, 45
Hillis A, 560
Hughes JR, 176

International Breast Cancer Study Group, 485

Jobe AH, 75
Johnson CA, 143
Johnson JW, 500

Keltner JL, 143
Kenny DJ, 123
Keogh JP, 308
Kiefer S, 538
Kimball B, 45
Kjelsberg MO, 20S
Korn EL, 286
Kusek JW, 3S, 538

Lachin JM, 471
Lakatos E, 350
Lange N, 247
Langenberg P, 467
Lee YJ, 179
Leedom JM, 523
Leite MLC, 296
LeMay M, 45
Lespérance J, 45
Louis TA, 252
Lund B, 325
Lung Health Study Research Group, 1S, 3S, 20S, 38S
Lunghofer B, 523

Manfreda J, 68S
Manske KA, 52S
Mark SD, 79
Marubini E, 296
Matts JP, 500
McKellar J, 568
McMahon RP, 244
Meinert CL, 255
Meyskens F, Jr, 308
Miller LL, 286
Moyé LA, 249, 350

ODES Investigators, 229
O'Hara P, 3S
Omenn GS, 308, 325
Optic Neuritis Study Group, 123, 143
Owens GR, 20S

Peterson B, 511
Petroccione A, 296
Pettit P, 261
Piantadosi S, 562
Pirotta N, 296
PMA Biostatistics and Medical Ad Hoc Committee on Interim Analysis, 160
POSCH Group, 500
Powers SN, 538
Pressel S, 350
Pritchett W, 6
Probstfield JL, 350

Recruitment Directors of the Lung Health Study for the Lung Health Study Research Group, 20S

0197-2456/93/$6.00

Controlled Clinical Trials 13:572–573 (1993)
© Elsevier Science Publishing Co., Inc. 1993
655 Avenue of the Americas, New York, New York, 10010

Redfield R, 6
Roberts R, 6
Robins JM, 79
Rosenberger WF, 471
Rosendorf LL, 523
Rosenstock L, 308
Rudick C, 68S

Senn S, 1
Shuster JJ, 198
Siebert C, 30
Silverman WA, 347
Simberkoff MS, 6
SINBA Group, 296
Spaeth GL, 174, 340
Spritz N, 6
Spurr JO, 143
Steinman TI, 538
Stibolt TB, 52S
Stuenkel MR, 500
Sukkestad E, 523

Tamhane AC, 19
Therneau TM, 98
Thornquist MD, 308, 325
Tonse NK, 467
Tseng A, 325
Tukey JW, 266

Urban N, 325

VA Cooperative Study Group on AIDS Treatment, 6
Valanis B, 308

Wara DW, 523
Waters D, 45
Wenzel RP, 6
Williams JH, Jr, 308
Wittes J, 350, 562
Wu M, 3S

Youtsey DJ, 52S
Yu KF, 286

Zavela KJ, 52S

Subject Index for Volume 14

ACCELERATED FAILURE TIME MODEL
A Method for the Analysis of Randomized Trials with Compliance Information: An Application to the Multiple Risk Factor Intervention Trial, 79

ACCIDENTAL BIAS
How Many Stratification Factors Are "Too Many" to Use in a Randomization Plan?, 98

ACTIVE CONTROL TRIALS
Monitoring of Clinical Trials: Issues and Recommendations, 183

ADAPTIVE ALLOCATION
How Many Stratification Factors Are "Too Many" to Use in a Randomization Plan?, 98

ADHERENCE
Research Cost Analyses to Aid in Decision Making in the Conduct of a Large Prevention Trial, CARET, 325

ADJUSTMENT FOR COVARIATES
Tightening the Clinical Trial, 266

ADMINISTRATIVE ANALYSES
Monitoring of Clinical Trials: Issues and Recommendations, 183

AIDS
Performance Evaluation in Multicenter Clinical Trials: Development of a Model by the AIDS Clinical Trial Group, 523

ALTHAM'S MODEL
"Within Patient"–Dependent Outcomes in Graft Occlusion After Coronary Artery Bypass, 296

AUTOMATED PERIMETRY
Quality Control Functions of the Visual Field Reading Center (VFRC) for the Optic Neuritis Treatment Trial (ONTT), 143

BAYESIAN ANALYSIS
Stopping a Clinical Trial Very Early Because of Toxicity: Summarizing the Evidence, 286

BEHAVIORAL INTERVENTION
Design of the Lung Health Study: A Randomized Clinical Trial of Early Intervention for Chronic Obstructive Pulmonary Disease, 3S

BERKSON'S SIMPLE DIFFERENCE
Exact Repeated Confidence Intervals for Bernoulli Parameters in a Group Sequential Clinical Trial, 19

BINOMIAL DISTRIBUTION
Exact Repeated Confidence Intervals for Bernoulli Parameters in a Group Sequential Clinical Trial, 19
Fixing the Number of Events in Large Comparative Trials With Low Event Rates: A Binomial Approach, 198

β-BINOMIAL MODEL
"Within Patient"–Dependent Outcomes in Graft Occlusion After Coronary Artery Bypass, 296

BLOOD PRESSURE MEASUREMENT
Note on the Value of 24-Hour Ambulatory Blood Pressure Devices (letter), 568

BOOK REVIEW
Medical Statistics: A Commonsense Approach, by Campbell MJ and Machin D, 251

CENSORED SURVIVAL DATA
Fixing the Number of Events in Large Comparative Trials With Low Event Rates: A Binomial Approach, 198

CENTRAL LABORATORY
In Response to an Article by Lemuel Moyé (CCT 12(6)) Entitled "Central Laboratory Sampling Plans and Quality Control in Clinical Trials" (letters), 244, 247

0197-2456/93/$6.00

Controlled Clinical Trials 13:574–581 (1993)
© Elsevier Science Publishing Co., Inc. 1993
655 Avenue of the Americas, New York, New York, 10010

CHEMOPREVENTION
Research Cost Analyses to Aid in Decision Making in the Conduct of a Large Prevention Trial, CARET, 325
Statistical Design and Monitoring of the Carotene and Retinol Efficacy Trial (CARET), 308

CHOLESTEROL REDUCTION
Effect of Cholesterol Reduction by Simvastatin on Progression of Coronary Atherosclerosis: Design, Baseline Characteristics, and Progress of the Multicenter Anti-Atheroma Study (MAAS), 209

CHOROIDAL MELANOMA
Design and Methods of a Clinical Trial for a Rare Condition: The Collaborative Ocular Melanoma Study, 362

CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Recruiting Healthy Participants for a Large Clinical Trial, 68S
Recruitment of Participants in the Lung Health Study, I: Description of Methods, 20S

CLINICAL TRIAL DESIGN
How Many Stratification Factors Are "Too Many" to Use in a Randomization Plan?, 98

CLINICAL TRIALS
A Computer Program for Designing Clinical Trials with Arbitrary Survival Curves and Group Sequential Testing, 109
Design of the Lung Health Study: A Randomized Clinical Trial of Early Intervention for Chronic Obstructive Pulmonary Disease, 3S
Ethical Dilemmas in Continuing a Zidovudine Trial After Early Termination of Similar Trials, 6
Exclusion of "Noncompliant" Individuals from Clinical Trials (letter), 176
Letters, 340, 344
Monitoring Recruitment Effectiveness and Cost in a Clinical Trial, 52S
The Oslo Diet and Exercise Study (ODES): Design and Objectives, 229
Politically Correct Clinical Trials (letter), 562
Quality Control Functions of the Visual Field Reading Center (VFRC) for the Optic Neuritis Treatment Trial (ONTT), 143
Recruiting Healthy Participants for a Large Clinical Trial, 68S
Recruitment of Participants in the Lung Health Study, I: Description of Methods, 20S
Recruitment of Participants in the Lung Health Study, II: Assessment of Recruiting Strategies, 38S
Resolution on Clinical Trials (letter), 560
Treatment Effect Size in Clinical Trials: An Example from Surfacant Trials, 467

COMPLIANCE
A Method for the Analysis of Randomized Trials with Compliance Information: An Application to the Multiple Risk Factor Intervention Trial, 79

COMPUTER PROGRAM
A Computer Program for Designing Clinical Trials with Arbitrary Survival Curves and Group Sequential Testing, 109

CONDITIONAL POWER
Statistical Considerations in Monitoring the Systolic Hypertension in the Elderly Program (SHEP), 350

CONFIDENCE INTERVAL
Stopping a Clinical Trial Very Early Because of Toxicity: Summarizing the Evidence, 286

CONTROLLED CLINICAL TRIAL
Design, Methods, and Conduct of the Optic Neuritis Treatment Trial, 123

CORONARY ATHEROSCLEROSIS
Design Features of a Controlled Clinical Trial to Assess the Effect of an HMG CoA Reductase Inhibitor on the Progression of Coronary Artery Disease, 45
Effect of Cholesterol Reduction by Simvastatin on Progression of Coronary Atherosclerosis: Design, Baseline Characteristics, and Progress of the Multicenter Anti-Atheroma Study (MAAS), 209

CORPORATE AUTHORSHIP
In Defense of the Corporate Author for Multicenter Trials, 255

COST(S)
Monitoring Recruitment Effectiveness and Cost in a Clinical Trial, 52S
Resolution on Clinical Trials (letter), 560

COST EFFECTIVENESS
Research Cost Analyses to Aid in Decision Making in the Conduct of a Large Prevention Trial, CARET, 325

DATA MONITORING
Response to McMahon and Lange (letter), 249
Statistical Considerations in Monitoring the Systolic Hypertension in the Elderly Program (SHEP), 350

DATA-MONITORING COMMITTEES
Monitoring of Clinical Trials: Issues and Recommendations, 183

DEATH
From "Tame" to "Forbidden" Death, 347

DEPENDENT OUTCOMES
"Within Patient"–Dependent Outcomes in Graft Occlusion After Coronary Artery Bypass, 296

DESIGN
Design and Methods of a Clinical Trial for a Rare Condition: The Collaborative Ocular Melanoma Study, 362

DIETARY TREATMENT
The Oslo Diet and Exercise Study (ODES): Design and Objectives, 229

DIETHYLSTILBESTROL
The 1953 Clinical Trial of Diethylstilbestrol During Pregnancy: Could It Have Stopped DES Use?, 179

DOCUMENTATION
Operational and Policy Considerations of Data Monitoring in Clinical Trials: The Diabetes Control and Complications Trial Experience, 30

DOUBLE RANDOMIZATION
Tightening the Clinical Trial, 266

EARLY STOPPING
Ethical Dilemmas in Continuing a Zidovudine Trial After Early Termination of Similar Trials, 6
Stopping a Clinical Trial Very Early Because of Toxicity: Summarizing the Evidence, 286

ENUCLEATION
Design and Methods of a Clinical Trial for a Rare Condition: The Collaborative Ocular Melanoma Study, 362

ERRATUM, 253

ETHICS
Ethical Dilemmas in Continuing a Zidovudine Trial After Early Termination of Similar Trials, 6
Instituting a Research Ethic, 261
The Use of Response-Adaptive Designs in Clinical Trials, 471

FACTORIAL DESIGN
Sample Size Requirements and Length of Study for Testing Interaction in a 1 X k Factorial Design when Time-to-Failure Is the Outcome, 511

FIBRINOLYSIS
The Oslo Diet and Exercise Study (ODES): Design and Objectives, 229

FISHER'S EXACT TEST
Fixing the Number of Events in Large Comparative Trials With Low Event Rates: A Binomial Approach, 198
Stopping a Clinical Trial Very Early Because of Toxicity: Summarizing the Evidence, 286

GLUCOSE METABOLISM
The Oslo Diet and Exercise Study (ODES): Design and Objectives, 229

GRAFT PATENCY
"Within Patient"–Dependent Outcomes in Graft Occlusion After Coronary Artery Bypass, 296

GROUP SEQUENTIAL DESIGN
A Computer Program for Designing Clinical Trials with Arbitrary Survival Curves and Group Sequential Testing, 109
Monitoring of Clinical Trials: Issues and Recommendations, 183
Stopping a Clinical Trial Very Early Because of Toxicity: Summarizing the Evidence, 286

GROUP SEQUENTIAL METHODS
Fixing the Number of Events in Large Comparative Trials With Low Event Rates: A Binomial Approach, 198

HEMOSTASIS
The Oslo Diet and Exercise Study (ODES): Design and Objectives, 229

HIV INFECTION
Ethical Dilemmas in Continuing a Zidovudine Trial After Early Termination of Similar Trials, 6

HMG-CoA REDUCTASE INHIBITORS
Design Features of a Controlled Clinical Trial to Assess the Effect of an HMG CoA Reductase Inhibitor on the Progression of Coronary Artery Disease, 45
Effect of Cholesterol Reduction by Simvastatin on Progression of Coronary Atherosclerosis: Design, Baseline Characteristics, and Progress of the Multicenter Anti-Atheroma Study (MAAS), 209

HYPERLIPIDEMIAS
Perception of Quality of Life Before and After Disclosure of Trial Results: A Report from the Program on the Surgical Control of Hyperlipidemias (POSCH), 500

ILIAL BYPASS
Perception of Quality of Life Before and After Disclosure of Trial Results: A Report from the Program on the Surgical Control of Hyperlipidemias (POSCH), 500

INFORMED CONSENT
Ethical Dilemmas in Continuing a Zidovudine Trial After Early Termination of Similar Trials, 6

INHALED BRONCHODILATOR
Design of the Lung Health Study: A Randomized Clinical Trial of Early Intervention for Chronic Obstructive Pulmonary Disease, 3S

INTERIM ANALYSIS
A Computer Program for Designing Clinical Trials with Arbitrary Survival Curves and Group Sequential Testing, 109
Exact Repeated Confidence Intervals for Bernoulli Parameters in a Group Sequential Clinical Trial, 19
Interim Analysis in the Pharmaceutical Industry, 160
Monitoring of Clinical Trials: Issues and Recommendations, 183

KINETIC PERIMETRY
Quality Control Functions of the Visual Field Reading Center (VFRC) for the Optic Neuritis Treatment Trial (ONTT), 143

LAG TIME
Statistical Considerations in Monitoring the Systolic Hypertension in the Elderly Program (SHEP), 350

LESS-THAN-PERFECT ADJUSTMENT
Tightening the Clinical Trial, 266

LETTERS TO THE EDITOR, 340, 344
Concerning Silverman's Suspended Judgment Article "The Most Noble Goal Of Medicine" Published December 1991, 174
Exclusion of "Noncompliant" Individuals from Clinical Trials, 176
In Response to an Article by Lemuel Moyé (CCT 12(6)) Entitled "Central Laboratory Sampling Plans and Quality Control in Clinical Trials," 244, 247
Note on the Value of 24-Hour Ambulatory Blood Pressure Devices, 568
Politically Correct Clinical Trials, 562
Resolution on Clinical Trials, 560
Response to McMahon and Lange, 249

LIPIDS AND LIPOPROTEINS
The Oslo Diet and Exercise Study (ODES): Design and Objectives, 229

LOG-RANK TEST
A Method for the Analysis of Randomized Trials with Compliance Information: An Application to the Multiple Risk Factor Intervention Trial, 79

LUNG CANCER
Statistical Design and Monitoring of the Carotene and Retinol Efficacy Trial (CARET), 308

LUNG DISEASE
Monitoring Recruitment Effectiveness and Cost in a Clinical Trial, 52S

LUNG HEALTH STUDY
APPENDIX, Lung Health Study Participants, 80S
Design of the Lung Health Study: A Randomized Clinical Trial of Early Intervention for Chronic Obstructive Pulmonary Disease, 3S
The Lung Health Study: Introduction, 1S
Monitoring Recruitment Effectiveness and Cost in a Clinical Trial, 52S
Recruiting Healthy Participants for a Large Clinical Trial, 68S
Recruitment of Participants in the Lung Health Study, I: Description of Methods, 20S
Recruitment of Participants in the Lung Health Study, II: Assessment of Recruiting Strategies, 38S

MARKOV-LIKE SUSCEPTIBILITY MODEL
"Within Patient"–Dependent Outcomes in Graft Occlusion After Coronary Artery Bypass, 296

METHODS
Design and Methods of a Clinical Trial for a Rare Condition: The Collaborative Ocular Melanoma Study, 362

METHODS OR ISSUES
Operational and Policy Considerations of Data Monitoring in Clinical Trials: The Diabetes Control and Complications Trial Experience, 30

MINIMAL DETECTABLE DIFFERENCE
Fixing the Number of Events in Large Comparative Trials With Low Event Rates: A Binomial Approach, 198

MONITORING RULES
Statistical Design and Monitoring of the Carotene and Retinol Efficacy Trial (CARET), 308

MULTICENTER CLINICAL TRIALS
In Defense of the Corporate Author for Multicenter Trials, 255
Performance Evaluation in Multicenter Clinical Trials: Development of a Model by the AIDS Clinical Trial Group, 523

NONCOMPLIANCE
Exclusion of "Noncompliant" Individuals from Clinical Trials (letter), 176

NUISANCE PARAMETER
Stopping a Clinical Trial Very Early Because of Toxicity: Summarizing the Evidence, 286

ODDS RATIO
Exact Repeated Confidence Intervals for Bernoulli Parameters in a Group Sequential Clinical Trial, 19

OPTIC NEURITIS
Design, Methods, and Conduct of the Optic Neuritis Treatment Trial, 123
Quality Control Functions of the Visual Field Reading Center (VFRC) for the Optic Neuritis Treatment Trial (ONTT), 143

ORGANIZATION
Operational and Policy Considerations of Data Monitoring in Clinical Trials: The Diabetes Control and Complications Trial Experience, 30

PARAMETRIC MODELS
Parametric Extrapolation of Survival Estimates with Applications to Quality of Life Evaluation of Treatments, 485

PHARMACEUTICAL INDUSTRY
Interim Analysis in the Pharmaceutical Industry, 160

PHYSICAL EXERCISE
The Oslo Diet and Exercise Study (ODES): Design and Objectives, 229

PHYSICIAN REFERRAL
Recruitment Experience in the Full-Scale Phase of the Modification of Diet in Renal Disease Study, 538

PLATINUM STANDARD
Tightening the Clinical Trial, 266

POWER
Fixing the Number of Events in Large Comparative Trials With Low Event Rates: A Binomial Approach, 198

PREGNANCY
The 1953 Clinical Trial of Diethylstilbestrol During Pregnancy: Could It Have Stopped DES Use?, 179

PROTOCOL-SPECIFIED ADJUSTMENT
Tightening the Clinical Trial, 266

PULMONARY FUNCTION
Design of the Lung Health Study: A Randomized Clinical Trial of Early Intervention for Chronic Obstructive Pulmonary Disease, 3S

QUALITY CONTROL
In Response to an Article by Lemuel Moyé (CCT 12(6)) Entitled "Central Laboratory Sampling Plans and Quality Control in Clinical Trials" (letters), 244, 247
Quality Control Functions of the Visual Field Reading Center (VFRC) for the Optic Neuritis Treatment Trial (ONTT), 143

QUALITY-OF-LIFE
Parametric Extrapolation of Survival Estimates with Applications to Quality of Life Evaluation of Treatments, 485
Perception of Quality of Life Before and After Disclosure of Trial Results: A Report from the Program on the Surgical Control of Hyperlipidemias (POSCH), 500

QUANTITAIVE ARTERIOGRAPHY
Design Features of a Controlled Clinical Trial to Assess the Effect of an HMG CoA Reductase Inhibitor on the Progression of Coronary Artery Disease, 45

QUANTITATIVE ANGIOGRAPHY
Effect of Cholesterol Reduction by Simvastatin on Progression of Coronary Atherosclerosis: Design, Baseline Characteristics, and Progress of the Multicenter Anti-Atheroma Study (MAAS), 209

RADIO THERAPY
Design and Methods of a Clinical Trial for a Rare Condition: The Collaborative Ocular Melanoma Study, 362

RANDOMIZATION
How Many Stratification Factors Are "Too Many" to Use in a Randomization Plan?, 98
The Use of Response-Adaptive Designs in Clinical Trials, 471

RANDOMIZATION ANALYSIS
Tightening the Clinical Trial, 266

RANDOMIZED CLINICAL TRIAL
A Method for the Analysis of Randomized Trials with Compliance Information: An Application to the Multiple Risk Factor Intervention Trial, 79
Recruitment Experience in the Full-Scale Phase of the Modification of Diet in Renal Disease Study, 538

RANDOMIZED PLAY-THE-WINNER RULE
The Use of Response-Adaptive Designs in Clinical Trials, 471

RANDOMIZED TRIAL
Design, Methods, and Conduct of the Optic Neuritis Treatment Trial, 123
The Oslo Diet and Exercise Study (ODES): Design and Objectives, 229

RARE CONDITION
Design and Methods of a Clinical Trial for a Rare Condition: The Collaborative Ocular Melanoma Study, 362

RECRUITMENT
Monitoring Recruitment Effectiveness and Cost in a Clinical Trial, 52S
Recruiting Healthy Participants for a Large Clinical Trial, 68S
Recruitment Experience in the Full-Scale Phase of the Modification of Diet in Renal Disease Study, 538
Recruitment of Participants in the Lung Health Study, I: Description of Methods, 20S
Recruitment of Participants in the Lung Health Study, II: Assessment of Recruiting Strategies, 38S

REGRESSION
Design Features of a Controlled Clinical Trial to Assess the Effect of an HMG CoA Reductase Inhibitor on the Progression of Coronary Artery Disease, 45

RELATIVE RISK
Exact Repeated Confidence Intervals for Bernoulli Parameters in a Group Sequential Clinical Trial, 19

REPEATED CONFIDENCE INTERVALS
Exact Repeated Confidence Intervals for Bernoulli Parameters in a Group Sequential Clinical Trial, 19
Monitoring of Clinical Trials: Issues and Recommendations, 183

SAMPLE SIZE
Fixing the Number of Events in Large Comparative Trials With Low Event Rates: A Binomial Approach, 198
Research Cost Analyses to Aid in Decision Making in the Conduct of a Large Prevention Trial, CARET, 325
Sample Size Requirements and Length of Study for Testing Interaction in a 1 X k Factorial Design when Time-to-Failure Is the Outcome, 511
Statistical Design and Monitoring of the Carotene and Retinol Efficacy Trial (CARET), 308
"Within Patient"–Dependent Outcomes in Graft Occlusion After Coronary Artery Bypass, 296

SCREENING
Recruitment of Participants in the Lung Health Study, II: Assessment of Recruiting Strategies, 38S

SEQUENTIAL ANALYSIS
Stopping a Clinical Trial Very Early Because of Toxicity: Summarizing the Evidence, 286

SIMVASTATIN
Effect of Cholesterol Reduction by Simvastatin on Progression of Coronary Atherosclerosis: Design, Baseline Characteristics, and Progress of the Multicenter Anti-Atheroma Study (MAAS), 209

SMOKING CESATION
A Method for the Analysis of Randomized Trials with Compliance Information: An Application to the Multiple Risk Factor Intervention Trial, 79

STATIC PERIMETRY
Quality Control Functions of the Visual Field Reading Center (VFRC) for the Optic Neuritis Treatment Trial (ONTT), 143

STOCHASTIC CURTAILMENT
Monitoring of Clinical Trials: Issues and Recommendations, 183
Statistical Considerations in Monitoring the Systolic Hypertension in the Elderly Program (SHEP), 350

STRATIFICATION
How Many Stratification Factors Are "Too Many" to Use in a Randomization Plan?, 98

SURFACANT TRIALS
Treatment Effect Size in Clinical Trials: An Example from Surfacant Trials, 467

SURVIVAL ANALYSIS
Parametric Extrapolation of Survival Estimates with Applications to Quality of Life Evaluation of Treatments, 485

SURVIVAL CURVES
A Computer Program for Designing Clinical Trials with Arbitrary Survival Curves and Group Sequential Testing, 109

SUSPENDED JUDGMENT
The 1953 Clinical Trial of Diethylstilbestrol During Pregnancy: Could it Have Stopped DES Use?, 179
Concerning Silverman's Suspended Judgment Article "The Most Noble Goal Of Medicine" Published December 1991 (letter), 174
Instituting a Research Ethic, 261
n-of-1 Trials, 1
Simple Explanations for Complex Systems: Surprising and Unexpected Outcomes, 75
From "Tame" to "Forbidden" death, 347
Treatment Effect Size in Clinical Trials: An Example from Surfactant Trials, 467

TIME DEPENDENT COVARIATE
A Method for the Analysis of Randomized Trials with Compliance Information: An Application to the Multiple Risk Factor Intervention Trial, 79

TIME-TO-FAILURE
Sample Size Requirements and Length of Study for Testing Interaction in a 1 X *k* Factorial Design when Time-to-Failure Is the Outcome, 511

TREATMENT ALLOCATION
The Use of Response-Adaptive Designs in Clinical Trials, 471

TREATMENT EFFECT SIZE
Treatment Effect Size in Clinical Trials: An Example from Surfacant Trials, 467

TREATMENT EFFECTS MONITORING
Operational and Policy Considerations of Data Monitoring in Clinical Trials: The Diabetes Control and Complications Trial Experience, 30

TREATMENT IMBALANCE
How Many Stratification Factors Are "Too Many" to Use in a Randomization Plan?, 98

VISUAL FIELDS
Quality Control Functions of the Visual Field Reading Center (VFRC) for the Optic Neuritis Treatment Trial (ONTT), 143

ZIDOVUDINE
Ethical Dilemmas in Continuing a Zidovudine Trial After Early Termination of Similar Trials, 6